At the beginning of 2021, ADMA Biologics started to gain momentum and significantly improved its price values. However, starting on February 9, the company experienced a decline. Today, the loss is equal to 45.97%.
The most recent peak was on February 9 of 2021 when the price peaked at $2.95. After this peak, the stock has sharply declined. Today, the value stands at $1.14. This is a $0.0200 and 1.79% increase since the previous close. ADMA Biologics is a commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics.
It announced on-demand access to an exclusive educational event on respiratory viral infections at IDWeek 2021, presented by nationally recognized clinical experts Dr. Michael Ison of Northwestern University and Dr. Jolan Walter of the University of South Florida. Dr. Walter highlighted real-world experiences with patients who were effectively treated with ADMA’s ASCENIVTM, a new intravenous immunoglobulin (IVIG) product with a unique composition, during the live presentation and question & answer session. The two examples provided comprehensive situations in which ASCENIV treatment resulted in significant improvements in the clinical course of two infants with primary immunodeficiency (PI) and RSV infection.